Diagnostic value of serum NSE, and S-100β and inflammatory markers levels in epilepsy
Abstract
Background To sodium valproate lore the effects of sodium valproate on serum inflammatory factors and s-100<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span> levels in patients with emergency secondary epilepsy(SE). Methods This was a retrospective cohort of 120 patients with SE who received Sodium valproate compared with a group who received carbamazepine for different therapeutic drugs. The general data, interleukin (IL)-2, IL-8, tumour necrosis factor (TNF)-<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span>, neuron-specific enolase (NSE), serum acid calcium-binding protein s-100<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span>, total effective rate (TER), seizure onset condition, and adverse reactions (Ars) of the two groups were compared at baseline and at 3 months later. Results There were no significant differences in age, gender, BMI, course of the disease, stroke type, or seizure type between the study groups (P> 0.05). The results showed that IL-2 of the Sodium valproate group (53.17± 4.95 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) was lower versus Carbamazepine group (62.38± 4.83 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) (P< 0.05). The IL-8 of the Sodium valproate group postoperatively (26.48± 2.73 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) was lower versus the Carbamazepine group (33.54± 3.39 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) (P< 0.05). Postoperatively, the TNF-<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">α</span> in Sodium valproate group (32.18± 4.26 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) was lower versus the Carbamazepine group (41.03± 4.92 <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L) (P< 0.05). The s-100<span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">β</span> (0.29 ± 0.15 ) <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L in the Sodium valproate group was lower versus the Carbamazepine group (0.54± 0.14) <span style="color: rgb(32, 33, 34); font-family: sans-serif; font-size: 16px; background-color: rgb(248, 249, 250);">μ</span>g/L (P < 0.05). The TER of the Sodium valproate group (93.33% ) was higher versus the Carbamazepine group of 75% (P < 0 .0 5 ). The number of epileptic seizures in the Sodium valproate group was 0.81± 0.08 times per year versus 1.23± 0.12 times per year in the Carbamazepine group. The duration of epilepsy in the Sodium valproate group (2.53± 0.22 min/time) was shorter than that in the Carbamazepine group (3.08 ± 0.24 min/time). Conclusions Sodium valproate can drastically relieve the epileptic symptoms of patients with SE, and there was no great difference in ARs. Hence, it is safe and worthy of popularization and application.